<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28606184</article-id><article-id pub-id-type="pmc">5469065</article-id><article-id pub-id-type="publisher-id">2018</article-id><article-id pub-id-type="doi">10.1186/s13063-017-2018-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Multicomponent intervention versus usual care for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: study protocol for a cluster randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Jafar</surname><given-names>Tazeen H.</given-names></name><address><phone>65-6601-2582</phone><email>tazeen.jafar@duke-nus.edu.sg</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jehan</surname><given-names>Imtiaz</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>de Silva</surname><given-names>H. Asita</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Naheed</surname><given-names>Aliya</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Gandhi</surname><given-names>Mihir</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Assam</surname><given-names>Pryseley</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Finkelstein</surname><given-names>Eric A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Quigley</surname><given-names>Helena Legido</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bilger</surname><given-names>Marcel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Aamir Hameed</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Clemens</surname><given-names>John David</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ebrahim</surname><given-names>Shah</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Turner</surname><given-names>Elizabeth L.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><collab>for COBRA-BPS Study Group</collab></contrib><contrib contrib-type="author"><name><surname>Kasturiratne</surname><given-names>Anuradhani</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 0924</institution-id><institution-id institution-id-type="GRID">grid.428397.3</institution-id><institution>Program in Health Services &amp; Systems Research, </institution><institution>Duke-NUS Medical School, </institution></institution-wrap>8 College Road, Singapore, 169857 Singapore </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7961</institution-id><institution-id institution-id-type="GRID">grid.26009.3d</institution-id><institution>Duke Global Health Institute, </institution><institution>Duke University, </institution></institution-wrap>Durham, NC USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0633 6224</institution-id><institution-id institution-id-type="GRID">grid.7147.5</institution-id><institution>Department of Community Health Sciences, </institution><institution>Aga Khan University, </institution></institution-wrap>Karachi, Pakistan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8631 5388</institution-id><institution-id institution-id-type="GRID">grid.45202.31</institution-id><institution>Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, </institution><institution>University of Kelaniya, </institution></institution-wrap>Ragama, Sri Lanka </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0600 7174</institution-id><institution-id institution-id-type="GRID">grid.414142.6</institution-id><institution></institution><institution>International Centre for Diarrhoeal Disease Research, </institution></institution-wrap>Dhaka, Bangladesh </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0451 6530</institution-id><institution-id institution-id-type="GRID">grid.452814.e</institution-id><institution></institution><institution>Biostatistics, Singapore Clinical Research Institute, </institution></institution-wrap>Singapore, 138669 Singapore </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 0924</institution-id><institution-id institution-id-type="GRID">grid.428397.3</institution-id><institution>Centre for Quantitative Medicine, </institution><institution>Duke-NUS Medical School, </institution></institution-wrap>Singapore, 16957 Singapore </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution>Saw Swee Hock School of Public Health, </institution><institution>National University of Singapore, </institution></institution-wrap>Singapore, 117549 Singapore </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0633 6224</institution-id><institution-id institution-id-type="GRID">grid.7147.5</institution-id><institution></institution><institution>Section of Cardiology, Aga Khan University, </institution></institution-wrap>Karachi, Pakistan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0425 469X</institution-id><institution-id institution-id-type="GRID">grid.8991.9</institution-id><institution></institution><institution>London School of Hygiene &amp; Tropical Medicine, </institution></institution-wrap>London, UK </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7961</institution-id><institution-id institution-id-type="GRID">grid.26009.3d</institution-id><institution>Department of Biostatistics and Bioinformatics, </institution><institution>Duke University, </institution></institution-wrap>Durham, NC USA </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>272</elocation-id><history><date date-type="received"><day>8</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>© The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="9069" xml_f="9079" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="9090" xml_f="9557" txt_i="22" txt_f="489">High blood pressure (BP) is the leading attributable risk for cardiovascular disease (CVD). In rural South Asia, hypertension continues to be a significant public health issue with sub-optimal BP control rates. The goal of the trial is to compare a multicomponent intervention (MCI) to usual care to evaluate the effectiveness and cost-effectiveness of the MCI for lowering BP among adults with hypertension in rural communities in Bangladesh, Pakistan and Sri Lanka.</offsets></p></sec><sec><title><offsets xml_i="9579" xml_f="9593" txt_i="491" txt_f="505">Methods/design</offsets></title><p><offsets xml_i="9604" xml_f="10392" txt_i="506" txt_f="1294">This study is a stratified, cluster randomized controlled trial with a qualitative component for evaluation of processes and stakeholder feedback. The MCI has five components: (1) home health education by government community health workers (CHWs), (2) BP monitoring and stepped-up referral to a trained general practitioner using a checklist, (3) training public and private providers in management of hypertension and using a checklist, (4) designating hypertension triage counter and hypertension care coordinators in government clinics and (5) a financing model to compensate for additional health services and provide subsidies to low income individuals with poorly controlled hypertension. Usual care will comprise existing services in the community without any additional training.</offsets></p><p><offsets xml_i="10399" xml_f="10908" txt_i="1295" txt_f="1804">The trial will be conducted on 2550 individuals aged ≥40 years with hypertension (with systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg, based on the mean of the last two of three measurements from two separate days, or on antihypertensive therapy) in 30 rural communities in Bangladesh, Pakistan and Sri Lanka. The primary outcome is change in systolic BP from baseline to follow-up at 24 months post-randomization. The incremental cost of MCI per CVD disability-adjusted life years averted will be computed.</offsets></p><p><offsets xml_i="10915" xml_f="11153" txt_i="1805" txt_f="2043">Stakeholders including policy makers, provincial- and district-level coordinators of relevant programmes, physicians, CHWs, key community leaders, hypertensive individuals and family members in the identified clusters will be interviewed.</offsets></p></sec><sec><title><offsets xml_i="11175" xml_f="11185" txt_i="2045" txt_f="2055">Discussion</offsets></title><p><offsets xml_i="11196" xml_f="11531" txt_i="2056" txt_f="2391">The study will provide evidence of the effectiveness and cost-effectiveness of MCI strategies for BP control compared to usual care in the rural public health infrastructure in South Asian countries. If shown to be successful, MCI may be a long-term sustainable strategy for tackling the rising rates of CVD in low resourced countries.</offsets></p></sec><sec><title><offsets xml_i="11553" xml_f="11571" txt_i="2393" txt_f="2411">Trial registration</offsets></title><p><offsets xml_i="11582" xml_f="11602" txt_i="2412" txt_f="2432">ClinicalTrials.gov, </offsets><ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02657746"><offsets xml_i="11697" xml_f="11708" txt_i="2432" txt_f="2443">NCT02657746</offsets></ext-link><offsets xml_i="11719" xml_f="11751" txt_i="2443" txt_f="2475">. Registered on 14 January 2016.</offsets></p></sec><sec><title><offsets xml_i="11773" xml_f="11806" txt_i="2477" txt_f="2510">Electronic supplementary material</offsets></title><p><offsets xml_i="11817" xml_f="11956" txt_i="2511" txt_f="2650">The online version of this article (doi:10.1186/s13063-017-2018-0) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hypertension</kwd><kwd>Lifestyle</kwd><kwd>Home health</kwd><kwd>Behaviour change</kwd><kwd>Cardiovascular risk</kwd><kwd>Public health</kwd><kwd>Cluster RCT</kwd></kwd-group><funding-group><award-group><funding-source><institution>Wellcome Trust/MRC/DfiD</institution></funding-source><award-id>MR/N006178/1</award-id><principal-award-recipient><name><surname>Jafar</surname><given-names>Tazeen H.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="12741" xml_f="12751" txt_i="2659" txt_f="2669">Background</offsets></title><p><offsets xml_i="12762" xml_f="12905" txt_i="2670" txt_f="2813">Cardiovascular disease (CVD) is a leading cause of mortality globally, accounting for 30% of deaths, even in low- and middle-income countries [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="12937" xml_f="12938" txt_i="2813" txt_f="2814">1</offsets></xref><offsets xml_i="12945" xml_f="12947" txt_i="2814" txt_f="2816">, </offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="12979" xml_f="12980" txt_i="2816" txt_f="2817">2</offsets></xref><offsets xml_i="12987" xml_f="13257" txt_i="2817" txt_f="3087">]. In South Asia, high rates of CVD are observed at a younger age than in other countries, causing a greater loss of productive life years with severe economic consequences. Population blood pressure (BP) levels and rates of hypertension continue to rise in South Asia [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="13289" xml_f="13290" txt_i="3087" txt_f="3088">3</offsets></xref><offsets xml_i="13297" xml_f="13299" txt_i="3088" txt_f="3090">].</offsets></p><p><offsets xml_i="13306" xml_f="13566" txt_i="3091" txt_f="3351">We have previously demonstrated the benefit of a model of care (COBRA: Control of Blood Pressure and Risk Attenuation), which combines family-based home health education (HHE) with trained private general practitioners (GPs), on lowering BP in urban Pakistan [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="13598" xml_f="13599" txt_i="3351" txt_f="3352">4</offsets></xref><offsets xml_i="13606" xml_f="14239" txt_i="3352" txt_f="3985">]. The combination of two interventions was superior than single or no intervention (usual care). However, the strategies were not evaluated in rural areas of Pakistan or any other South Asian country. Moreover, the urban model did not use the public health infrastructure for care delivery. Most of South Asia is still rural, where the prevalence of hypertension is high (one in four adults suffers from hypertension, and most cases are poorly controlled), and cardiovascular case fatality rates have been shown to be higher than in urban areas. Thus, evidence-based interventions applicable to rural South Asia are urgently needed.</offsets></p><p><offsets xml_i="14246" xml_f="14525" txt_i="3986" txt_f="4265">Recently, we reported findings from a feasibility study to modify the COBRA model of care as a multicomponent intervention (MCI) for optimal delivery using the public health infrastructure in rural regions in Bangladesh, Pakistan and Sri Lanka (the COBRA-BPS feasibility study) [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="14557" xml_f="14558" txt_i="4265" txt_f="4266">5</offsets></xref><offsets xml_i="14565" xml_f="15150" txt_i="4266" txt_f="4851">]. The feasibility study also explored system-level barriers and facilitators of implementation of the MCI. Common standardized protocols and manuals for training community health workers (CHWs) and GPs in all three countries were developed. The feedback and suggestions from the stakeholders have already been incorporated in the full-scale trial protocol to be evaluated for fidelity, effectiveness and cost-effectiveness of the MCI model of care that we refined based on the COBRA-BPS feasibility study. The current protocol paper describes the full-scale COBRA-BPS trial in detail.</offsets></p></sec><sec id="Sec2"><title><offsets xml_i="15182" xml_f="15196" txt_i="4853" txt_f="4867">Methods/design</offsets></title><p><offsets xml_i="15207" xml_f="15661" txt_i="4868" txt_f="5322">We will evaluate the effectiveness of the MCI model of care compared to usual care in lowering systolic blood pressure (SBP) levels over 2 years among 2550 individuals aged 40 years or older with hypertension (those with SBP ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg based on the mean of the last two of three measurements from two separate days, or on antihypertensive therapy) in 30 rural communities in Bangladesh, Pakistan and Sri Lanka.</offsets></p><p><offsets xml_i="15668" xml_f="16153" txt_i="5323" txt_f="5808">The MCI has five components: (1) HHE by government CHWs, (2) BP monitoring and stepped-up referral to a trained GP using a checklist, (3) training public and private providers in management of hypertension and using a checklist, (4) designating hypertension triage counter and hypertension care coordinators in government clinics and (5) a financing model to compensate for additional health services and provide subsidies to low income individuals with poorly controlled hypertension.</offsets></p><sec id="Sec3"><title><offsets xml_i="16179" xml_f="16216" txt_i="5809" txt_f="5846">Main and additional aims of the trial</offsets></title><p><offsets xml_i="16227" xml_f="16258" txt_i="5847" txt_f="5878">The main aims of the trial are:</offsets><list list-type="order"><list-item><p><offsets xml_i="16296" xml_f="16454" txt_i="5878" txt_f="6036">To evaluate whether the MCI (described with components 1–5 above) is better than usual care in lowering BP among adults with hypertension in rural communities</offsets></p></list-item><list-item><p><offsets xml_i="16484" xml_f="16715" txt_i="6037" txt_f="6268">To quantify the incremental cost-effectiveness of the MCI approach in terms of cost per projected cardiovascular disease disability-adjusted life years (CVD DALYs) averted from the societal, government and participant perspectives.</offsets></p></list-item></list><offsets xml_i="16738" xml_f="16739" txt_i="6269" txt_f="6270">
</offsets></p><p><offsets xml_i="16746" xml_f="16766" txt_i="6271" txt_f="6291">Additional aims are:</offsets><list list-type="simple"><list-item><label><offsets xml_i="16809" xml_f="16811" txt_i="6291" txt_f="6293">3.</offsets></label><p><offsets xml_i="16822" xml_f="17025" txt_i="6293" txt_f="6496">To determine whether MCI improves medication adherence and lowers body mass index (BMI), dietary sodium, smoking rates, lipid levels, glucose levels and INTERHEART CVD risk score relative to usual care [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="17057" xml_f="17058" txt_i="6496" txt_f="6497">6</offsets></xref><offsets xml_i="17065" xml_f="17066" txt_i="6497" txt_f="6498">]</offsets></p></list-item><list-item><label><offsets xml_i="17100" xml_f="17102" txt_i="6499" txt_f="6501">4.</offsets></label><p><offsets xml_i="17113" xml_f="17506" txt_i="6501" txt_f="6888">To determine whether MCI will lead to a greater reduction in 24-h ambulatory blood pressure among individuals with poorly controlled hypertension (defined as those with persistently elevated SBP &gt;140 mm Hg or DBP &gt;90 mm Hg mean of last two of three measurements from two separate days and receiving antihypertensive medications) in rural communities in Bangladesh, Pakistan and Sri Lanka</offsets></p></list-item></list><offsets xml_i="17529" xml_f="17530" txt_i="6889" txt_f="6890">
</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="17562" xml_f="17578" txt_i="6892" txt_f="6908">Qualitative aims</offsets></title><p><offsets xml_i="17589" xml_f="18017" txt_i="6909" txt_f="7337">A complementary qualitative study is planned in the MCI arm with the following objectives: (1) to understand facilitators and barriers to MCI from a stakeholder perspective and (2) to seek the hypertensive individuals’ experience during the course of MCI strategy in relation to components of the intervention, diagnosis of hypertension, treatment, quality of life and sustainability of intervention through in-depth interviews.</offsets></p><p><offsets xml_i="18024" xml_f="18075" txt_i="7338" txt_f="7389">The central hypotheses of the study are as follows:</offsets><list list-type="order"><list-item><p><offsets xml_i="18113" xml_f="18269" txt_i="7389" txt_f="7545">MCI will be more effective relative to usual care in lowering the BP of adults with hypertension in rural communities in Bangladesh, Pakistan and Sri Lanka.</offsets></p></list-item><list-item><p><offsets xml_i="18299" xml_f="18417" txt_i="7546" txt_f="7664">MCI will be more cost-effective relative to usual care when measured against common thresholds for cost-effectiveness.</offsets></p></list-item></list><offsets xml_i="18440" xml_f="18441" txt_i="7665" txt_f="7666">
</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="18473" xml_f="18485" txt_i="7668" txt_f="7680">Trial design</offsets></title><p><offsets xml_i="18496" xml_f="18737" txt_i="7681" txt_f="7922">The study is a stratified cluster randomized controlled trial (RCT) in rural communities in three South Asian countries conducted according to the UK Medical Research Council’s (MRC’s) framework for implementing complex intervention trials [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="18769" xml_f="18770" txt_i="7922" txt_f="7923">5</offsets></xref><offsets xml_i="18777" xml_f="19365" txt_i="7923" txt_f="8507">]. A cohort of 850 individuals with hypertension will be recruited in each country and followed over a 2-year period in order to be able to evaluate the BP change within individuals. Ethical approval has been obtained from the Ethics Review Committees of the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) Aga Khan University, the University of Kelaniya, the London School of Hygiene &amp; Tropical Medicine (LSHTM) and Duke-NUS Singapore. A Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist is provided as Additional file </offsets><xref rid="MOESM1" ref-type="media"><offsets xml_i="19401" xml_f="19402" txt_i="8507" txt_f="8508">1</offsets></xref><offsets xml_i="19409" xml_f="19458" txt_i="8508" txt_f="8557">. The SPIRIT deliverable items are shown in Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="19490" xml_f="19491" txt_i="8557" txt_f="8558">1</offsets></xref><offsets xml_i="19498" xml_f="19560" txt_i="8558" txt_f="8620">. The flow diagram for the study protocol is included as Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="19592" xml_f="19593" txt_i="8620" txt_f="8621">2</offsets></xref><offsets xml_i="19600" xml_f="19601" txt_i="8621" txt_f="8622">.</offsets><fig id="Fig1"><label><offsets xml_i="19623" xml_f="19629" txt_i="8622" txt_f="8628">Fig. 1</offsets></label><caption><p><offsets xml_i="19649" xml_f="19662" txt_i="8628" txt_f="8641">SPIRIT figure</offsets></p></caption><graphic xlink:href="13063_2017_2018_Fig1_HTML" id="MO1"></graphic></fig><offsets xml_i="19749" xml_f="19750" txt_i="8642" txt_f="8643">
</offsets><fig id="Fig2"><label><offsets xml_i="19772" xml_f="19778" txt_i="8643" txt_f="8649">Fig. 2</offsets></label><caption><p><offsets xml_i="19798" xml_f="19913" txt_i="8649" txt_f="8764">Study flow diagram. † Participants who successfully completed 2 years of follow-up will be included in the analyses</offsets></p></caption><graphic xlink:href="13063_2017_2018_Fig2_HTML" id="MO2"></graphic></fig><offsets xml_i="20000" xml_f="20001" txt_i="8765" txt_f="8766">
</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="20033" xml_f="20064" txt_i="8768" txt_f="8799">Trial setting and randomization</offsets></title><p><offsets xml_i="20075" xml_f="21624" txt_i="8800" txt_f="10349">The trial will be conducted in Bangladesh, Tangail District (population 3.2 million) and Munshiganj District (population 1.4 million); Pakistan, Thatta District (population 1.5 million); and Sri Lanka, Puttalam District (population 1.6 million). The unit of randomization will be a cluster defined by 250–300 households as defined by local administration according to CHW catchment area (each served by one to two CHWs). These clusters are grouped in geographically contiguous administrative units (AUs) as defined by the local governments (12 sub-districts in Tangail, 6 sub-districts in Munshignaj, 30 union councils in Thatta, 12 medical officers of the health division in Puttalam District) such that each unit is served by one government clinic. First, in the selected district of each country, 10 administrative units will be deliberately sampled, and the respective government clinic will be determined. Within each AU in each country, an eligible cluster will be identified (one cluster is defined as a village for Bangladesh, two to five neighbouring villages for Pakistan and two Grama Niladhari (GN) divisions for Sri Lanka). Each country will measure the distance of clusters from the respective government clinic measured by a GPS device. In each AU, clusters will be stratified by their distance to respective government clinic into two strata: FAR and NEAR (a distance of 2 km or less will be defined as NEAR and more than 2 km as FAR). In each arm (usual care or MCI), five AUs will be further randomized into three NEAR and two FAR.</offsets></p><p><offsets xml_i="21631" xml_f="22188" txt_i="10350" txt_f="10907">One NEAR cluster from each NEAR AU and one FAR cluster from each FAR AU will be randomly selected for subject recruitment. A minimum distance of 10 km between randomized clusters will be ensured. Randomization will be stratified by country as well as by the distance from the government clinic, and AUs will be randomized in a 1:1 ratio to either MCI or usual care within the six strata defined by the combination of country and distance (NEAR versus FAR) using a computer-generated randomization program at Singapore Clinical Research Institute, Singapore.</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="22220" xml_f="22247" txt_i="10909" txt_f="10936">Eligibility and recruitment</offsets></title><p><offsets xml_i="22258" xml_f="22301" txt_i="10937" txt_f="10980">Inclusion criteria include individuals who:</offsets><list list-type="order"><list-item><p><offsets xml_i="22339" xml_f="22359" txt_i="10980" txt_f="11000">Are of age ≥40 years</offsets></p></list-item><list-item><p><offsets xml_i="22389" xml_f="22420" txt_i="11001" txt_f="11032">Reside in the selected clusters</offsets></p></list-item><list-item><p><offsets xml_i="22450" xml_f="22486" txt_i="11033" txt_f="11069">Have hypertension defined either as:</offsets><list list-type="alpha-lower"><list-item><p><offsets xml_i="22530" xml_f="22729" txt_i="11069" txt_f="11268">Persistently elevated BP (SBP ≥140 mm Hg or DBP ≥90 mm Hg) from each set of last two of three readings from two separate days, where BP measurements on the same day were measured at least 3 min apart</offsets></p></list-item><list-item><p><offsets xml_i="22759" xml_f="22805" txt_i="11269" txt_f="11315">Are maintained on antihypertensive medications</offsets></p></list-item></list><offsets xml_i="22828" xml_f="22829" txt_i="11316" txt_f="11317">
</offsets></p></list-item><list-item><p><offsets xml_i="22859" xml_f="22895" txt_i="11318" txt_f="11354">Are willing to give informed consent</offsets></p></list-item></list><offsets xml_i="22918" xml_f="22919" txt_i="11355" txt_f="11356">
</offsets></p><p><offsets xml_i="22926" xml_f="22953" txt_i="11357" txt_f="11384">Exclusion criteria include:</offsets><list list-type="order"><list-item><p><offsets xml_i="22991" xml_f="23057" txt_i="11384" txt_f="11450">Permanently bedridden individuals too ill to commute to the clinic</offsets></p></list-item><list-item><p><offsets xml_i="23087" xml_f="23218" txt_i="11451" txt_f="11582">Pregnant women or individuals with advanced medical disease (those on dialysis, with liver failure or with other systemic diseases)</offsets></p></list-item><list-item><p><offsets xml_i="23248" xml_f="23324" txt_i="11583" txt_f="11659">Individuals who are mentally compromised and unable to give informed consent</offsets></p></list-item></list><offsets xml_i="23347" xml_f="23348" txt_i="11660" txt_f="11661">
</offsets></p></sec><sec id="Sec8"><title><offsets xml_i="23380" xml_f="23392" txt_i="11663" txt_f="11675">Intervention</offsets></title><p><offsets xml_i="23403" xml_f="23547" txt_i="11676" txt_f="11820">The MCI will be rolled out in the 15 clusters assigned to the intervention in the three countries (five in each). Components of the MCI include:</offsets><list list-type="order"><list-item><p><offsets xml_i="23585" xml_f="23586" txt_i="11820" txt_f="11821">
</offsets><italic><offsets xml_i="23594" xml_f="23641" txt_i="11821" txt_f="11868">Home health education (HHE) by government CHWs:</offsets></italic><offsets xml_i="23650" xml_f="23784" txt_i="11868" txt_f="12002"> The standardized curricula have been adapted to local diets and languages in the three countries during the pilot feasibility study [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="23816" xml_f="23817" txt_i="12002" txt_f="12003">5</offsets></xref><offsets xml_i="23824" xml_f="24027" txt_i="12003" txt_f="12206">]. Training for CHWs in conveying HHE using a structured behaviour change communication approach will be carried out by a qualified nutritionist for 3.5 h/day over 5 days (see details in Additional file </offsets><xref rid="MOESM2" ref-type="media"><offsets xml_i="24063" xml_f="24064" txt_i="12206" txt_f="12207">2</offsets></xref><offsets xml_i="24071" xml_f="24209" txt_i="12207" txt_f="12345">). During this time the CHWs will also be trained in completing a paper-based HHE checklist developed as part of the MCI (Additional file </offsets><xref rid="MOESM3" ref-type="media"><offsets xml_i="24245" xml_f="24246" txt_i="12345" txt_f="12346">3</offsets></xref><offsets xml_i="24253" xml_f="24609" txt_i="12346" txt_f="12702">). The health messages include information on the deleterious effects of hypertension, non-pharmacological interventions for preventing and controlling hypertension and CVD, along with advice on weight loss strategies, physical activity, smoking cessation, avoiding excessive alcohol, low salt and saturated fat intake, and high fruit and vegetable intake.</offsets></p><p><offsets xml_i="24616" xml_f="25275" txt_i="12703" txt_f="13362">The trained CHWs will go door to door and deliver the sessions every 3 months in each cluster (about 60 households with hypertension) per CHW — a caseload consistent with the existing services. CHWs will deliver HHE to all individuals with elevated BP (SBP ≥140 mm Hg or DBP ≥ 90 mm Hg) at any visit. The first HHE session is expected to run for one hour with the second session expected to last 30 minutes. Family members (including those without hypertension) are also invited to sit in the sessions. The HHE Checklist will be completed by the CHW at the end of the session and submitted to the Local Health Office (LHO) via the community health supervisor.</offsets></p></list-item><list-item><p><offsets xml_i="25305" xml_f="25306" txt_i="13363" txt_f="13364">
</offsets><italic><offsets xml_i="25314" xml_f="25383" txt_i="13364" txt_f="13433">BP monitoring, and stepped-up referral to trained GP using checklist:</offsets></italic><offsets xml_i="25392" xml_f="25823" txt_i="13433" txt_f="13864"> Every government CHW in the 15 intervention clusters will have a digital portable BP device (Omron HEM-7300™ Blood Pressure Monitor) and will be rigorously trained in standardized methods for BP measurement. CHWs will monitor the BP of all individuals aged 40 years or older with hypertension (as defined at baseline) at 3-monthly intervals and will complete the CHW BP monitoring and HHE checklist at each visit (Additional file </offsets><xref rid="MOESM3" ref-type="media"><offsets xml_i="25859" xml_f="25860" txt_i="13864" txt_f="13865">3</offsets></xref><offsets xml_i="25867" xml_f="26113" txt_i="13865" txt_f="14111">) including list of HHE sessions delivered. All individuals with poorly controlled BP (SBP ≥160 mm Hg or DBP ≥100 mm Hg) at any visit will be referred to a trained GP. The CHW will complete and submit the GP management checklist (Additional file </offsets><xref rid="MOESM4" ref-type="media"><offsets xml_i="26149" xml_f="26150" txt_i="14111" txt_f="14112">4</offsets></xref><offsets xml_i="26157" xml_f="26204" txt_i="14112" txt_f="14159">) to the CHW supervisor to track the referrals.</offsets></p></list-item><list-item><p><offsets xml_i="26234" xml_f="26235" txt_i="14160" txt_f="14161">
</offsets><italic><offsets xml_i="26243" xml_f="26327" txt_i="14161" txt_f="14245">Training providers in BP monitoring, management of hypertension and using checklist:</offsets></italic><offsets xml_i="26336" xml_f="27275" txt_i="14245" txt_f="15184"> As in the feasibility study, GPs and midlevel providers (nurses, pharmacists) in public and private clinics will be invited for training. All providers will be trained in standardized BP measurement. In addition, GPs will be trained in management of hypertension. The Hypertension Management Manual for Clinic Providers has been developed during the pilot feasibility study and includes training on (1) measurement of BP, (2) provision of lifestyle advice, (3) prescription of antihypertensive therapy and (4) risk stratification for lipid lowering. Those individuals with any of the following will be classified as being at ‘high risk for CVD’: (a) aged 55 years older with SBP ≥160 mm Hg (b) past history of diabetes, (c) past history of heart disease, (d) past history of stroke or (e) current smokers; these individuals will be initiated on statins. The GPs will also be trained in completing a GP referral checklist (Additional file </offsets><xref rid="MOESM5" ref-type="media"><offsets xml_i="27311" xml_f="27312" txt_i="15184" txt_f="15185">5</offsets></xref><offsets xml_i="27319" xml_f="27502" txt_i="15185" txt_f="15368">). A pre- and post-test of knowledge and practices will be administered. As in the feasibility study, we anticipate at least 66% of all GPs in the intervention clusters to be trained.</offsets></p></list-item><list-item><p><offsets xml_i="27532" xml_f="27533" txt_i="15369" txt_f="15370">
</offsets><italic><offsets xml_i="27541" xml_f="27641" txt_i="15370" txt_f="15470">Designating hypertension triage counter and hypertension care coordinator at the government clinics:</offsets></italic><offsets xml_i="27650" xml_f="28237" txt_i="15470" txt_f="16057"> A functional hypertension triage counter will be established at the government health clinic enrolled in the study. This triage counter will facilitate care of hypertensive individuals who present to the clinic with a GP referral checklist. The counter will be equipped with a digital BP device for standardized measurement of BP by a trained clinic nurse/assistant before evaluation by a trained physician. Additionally, a hypertension care coordinator will be appointed at each government clinic to facilitate tracking of referrals by the CHW of individuals with poorly controlled BP.</offsets></p></list-item><list-item><p><offsets xml_i="28267" xml_f="28268" txt_i="16058" txt_f="16059">
</offsets><italic><offsets xml_i="28276" xml_f="28343" txt_i="16059" txt_f="16126">Compensation for additional health services and targeted subsidies:</offsets></italic><offsets xml_i="28352" xml_f="29064" txt_i="16126" txt_f="16838"> The government CHWs will receive a pre-decided compensation of up to 0.2 FTE equivalent upon submission of the CHW BP monitoring and HHE checklist. Hypertensive individuals who are deemed poor (according to local policy in each country developed by the study team) with poorly controlled BP (SBP ≥160 or DBP ≥100 mm Hg) will receive a travel voucher for a clinic visit, and a free supply of antihypertensive medications will be provided. However, each country will have the flexibility to conform the subsidies to fit within the existing models of disbursements used in their respective systems, ensuring appropriate vetting for means testing, logistics and accountability of disbursement policy and procedures.</offsets></p></list-item></list><offsets xml_i="29087" xml_f="29088" txt_i="16839" txt_f="16840">
</offsets></p><sec id="Sec9"><title><offsets xml_i="29114" xml_f="29133" txt_i="16841" txt_f="16860">Treatment algorithm</offsets></title><p><offsets xml_i="29144" xml_f="29406" txt_i="16861" txt_f="17123">A standardized protocol has been developed and refined by study nephrologists, cardiologists, internists and family physicians using non-pharmacologic and pharmacologic interventions following National Institute for Health and Care Excellence (NICE) guidelines [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="29438" xml_f="29439" txt_i="17123" txt_f="17124">7</offsets></xref><offsets xml_i="29446" xml_f="29954" txt_i="17124" txt_f="17626">]. The antihypertensive agents include calcium channel blockers (CCBs), angiotensin-converting-enzyme (ACE) inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and thiazide-like diuretics. The target BP will be SBP &lt;140 mm Hg and DBP &lt;90 mm Hg for all participants. Individuals with hypertension classified as being at ‘high risk for CVD’ based on the risk stratification will be treated with statins. Details are provided in the Antihypertensive Medication Treatment Algorithm (Additional file </offsets><xref rid="MOESM6" ref-type="media"><offsets xml_i="29990" xml_f="29991" txt_i="17626" txt_f="17627">6</offsets></xref><offsets xml_i="29998" xml_f="30132" txt_i="17627" txt_f="17761">). As in the pilot feasibility study, prescription of inexpensive, generic antihypertensive medicines and statins has been encouraged.</offsets></p></sec></sec><sec id="Sec10"><title><offsets xml_i="30171" xml_f="30181" txt_i="17764" txt_f="17774">Usual care</offsets></title><p><offsets xml_i="30192" xml_f="30732" txt_i="17775" txt_f="18315">Usual care will comprise existing services in the community without any additional training. Services include government health worker home visits for preventive maternal and child health and family planning services. However, these do not include formal screening or monitoring of BP or lifestyle advice for the prevention of hypertension. The existing clinic GPs in the communities (public and private) cater to 50–70 hypertensive individuals/day with an average contact time of 5–10 min per individual (per the pilot feasibility study) [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="30764" xml_f="30765" txt_i="18315" txt_f="18316">5</offsets></xref><offsets xml_i="30772" xml_f="31079" txt_i="18316" txt_f="18623">]. Whereas these providers are accustomed to providing care for common childhood illnesses and infectious diseases (diarrhoea, fever, malaria) that have traditionally burdened developing countries, the systems are not well organized for treatment of non-communicable diseases (NCDs), including hypertension.</offsets></p><p><offsets xml_i="31086" xml_f="31316" txt_i="18624" txt_f="18854">Thus, usual care services do not include formal screening or monitoring BP or lifestyle advice for either prevention or management of hypertension; however, these services are included in the multicomponent intervention (MCI) arm.</offsets></p></sec><sec id="Sec11"><title><offsets xml_i="31349" xml_f="31387" txt_i="18856" txt_f="18894">Screening and baseline data collection</offsets></title><p><offsets xml_i="31398" xml_f="31937" txt_i="18895" txt_f="19434">The research staff masked to randomization status will first obtain a list of all members living in the households in the selected clusters from the Local Health Office and will visit all adults aged 40 years and older. Informed consent will be obtained for participation in the study. Those who consent will be screened for eligibility into the study. Standardized BP will be measured three times by research staff with a calibrated automated device, the Omron HEM-7300™ Blood Pressure Monitor, with the individual in a sitting position [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="31969" xml_f="31970" txt_i="19434" txt_f="19435">8</offsets></xref><offsets xml_i="31977" xml_f="31978" txt_i="19435" txt_f="19436">–</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="32011" xml_f="32013" txt_i="19436" txt_f="19438">10</offsets></xref></p><p><offsets xml_i="32027" xml_f="32439" txt_i="19439" txt_f="19851">An interviewer-administered questionnaire translated into the local languages (Bangla, Urdu, Sindhi, Sinhala and Tamil) will be presented. Domains include socio-demographics, diet, lifestyle and behaviour, co-morbidities and health-related quality of life (EQ-5D-5L), health-seeking behaviours and associated costs. Adherence to antihypertensives and statins will be assessed by administering the Morisky scale [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="32472" xml_f="32474" txt_i="19851" txt_f="19853">11</offsets></xref><offsets xml_i="32481" xml_f="32678" txt_i="19853" txt_f="20050">]. Adiposity measures will be recorded. Fasting blood samples will be collected for plasma glucose, serum creatinine and lipids, and a morning spot urine sample for sodium, albumin and creatinine [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="32711" xml_f="32713" txt_i="20050" txt_f="20052">12</offsets></xref><offsets xml_i="32720" xml_f="32722" txt_i="20052" txt_f="20054">, </offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="32755" xml_f="32757" txt_i="20054" txt_f="20056">13</offsets></xref><offsets xml_i="32764" xml_f="32766" txt_i="20056" txt_f="20058">].</offsets></p><p><offsets xml_i="32773" xml_f="33207" txt_i="20059" txt_f="20487">In each of the 30 clusters, participants on antihypertensive medications with uncontrolled hypertension (defined as persistently elevated SBP &gt;140 mm Hg or DBP &gt;90 mm Hg from each set of two readings from 2 separate days) will be offered informed consent to undergo 24-h ambulatory BP monitoring (ABPM) with the Ultralight 90207™ model. Subjects meeting the eligibility criteria will be recruited consecutively (14 per cluster).</offsets></p><p><offsets xml_i="33214" xml_f="33886" txt_i="20488" txt_f="21160">The MCI will be rolled out in the 15 clusters assigned to the intervention in three countries (five clusters in each). The CHW will then visit the household for HHE and will refer the individuals using the assigned GP referral checklist. The MCI team (including trainers and oversight personnel) and data collectors will be separate teams in each country. Although maintaining blinding at an operational level is challenging given the pragmatic nature of the MCI, measures will be taken to maintain masking of data collectors to randomization status by avoiding overlapping responsibilities of research data collectors and service delivery teams in the health care sector.</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="33919" xml_f="33939" txt_i="21162" txt_f="21182">Outcome measurements</offsets></title><p><offsets xml_i="33950" xml_f="34346" txt_i="21183" txt_f="21579">Outcome assessors masked to randomization status will pay 6-monthly home visits for a total of 2 years. BP will be measured with the calibrated automated device Omron HEM-7300™ Blood Pressure Monitor (as in the baseline) with the hypertensive individual in the sitting position. Readings will be taken 3 min apart. The average of the last two of three readings will be considered in the analysis.</offsets></p><p><offsets xml_i="34353" xml_f="34990" txt_i="21580" txt_f="22217">Information on behavioural risk factors (diet, physical activity, tobacco use and adiposity measures) will be obtained via an interviewer-administered questionnaire. Individuals will be asked to keep a record of the number of visits to the providers, type of facility (public or private), transportation costs, receipts of purchase of drugs and hospital visits. Based on our previous experience in urban Pakistan and the feasibility study in rural communities, the subjects are likely to maintain the records when requested in advance. Moreover, local information on market rates will be collected to supplement any missing information [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="35022" xml_f="35023" txt_i="22217" txt_f="22218">5</offsets></xref><offsets xml_i="35030" xml_f="35032" txt_i="22218" txt_f="22220">, </offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="35065" xml_f="35067" txt_i="22220" txt_f="22222">14</offsets></xref><offsets xml_i="35074" xml_f="35194" txt_i="22222" txt_f="22342">]. Information on serious adverse events including death, hospitalization and any other serious events will be recorded.</offsets></p><p><offsets xml_i="35201" xml_f="35340" txt_i="22343" txt_f="22482">The 24-h ABPM will be repeated at year 1 and at the final visit at year 2 post-randomization on the cohort enrolled in the ancillary study.</offsets></p><sec id="Sec13"><title><offsets xml_i="35367" xml_f="35396" txt_i="22483" txt_f="22512">Primary effectiveness measure</offsets></title><p><offsets xml_i="35407" xml_f="35621" txt_i="22513" txt_f="22727">The primary effectiveness measure is change in SBP from baseline to final follow-up at 2 years post-randomization. Both measurements will be taken by independent data collectors who will be masked to randomization.</offsets></p></sec><sec id="Sec14"><title><offsets xml_i="35654" xml_f="35686" txt_i="22729" txt_f="22761">Secondary effectiveness measures</offsets></title><p><offsets xml_i="35697" xml_f="36047" txt_i="22762" txt_f="23106">The secondary effectiveness measures are as follows: (1) BP controlled to target (SBP &lt;140 mm Hg and DBP &lt;90 mm Hg; (2) composite outcome of death (all cause) or hospital admission due to coronary heart disease (CHD), heart failure or stroke; (3) incremental cost per quality-adjusted life year (QALY) gained from baseline to end of follow-up [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="36080" xml_f="36082" txt_i="23106" txt_f="23108">15</offsets></xref><offsets xml_i="36089" xml_f="36090" txt_i="23108" txt_f="23109">–</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="36123" xml_f="36125" txt_i="23109" txt_f="23111">17</offsets></xref><offsets xml_i="36132" xml_f="36626" txt_i="23111" txt_f="23605">]; (4) change in antihypertensive medication adherence; (5) change in BMI; (6) change in dietary salt intake (urinary excretion); (7) change in prevalence of current smokers; (8) incident diabetes; (9) change in serum lipid levels; (10) change in INTERHEART CVD risk score; (11) incidence of adverse outcomes (medication side effects, sick days absenteeism, low QALY between randomized groups); (12) change in estimated glomerular filtration rate (eGFR); (13) change in urine albumin excretion.</offsets></p></sec><sec id="Sec15"><title><offsets xml_i="36659" xml_f="36694" txt_i="23607" txt_f="23642">Primary cost-effectiveness measures</offsets></title><p><offsets xml_i="36705" xml_f="36938" txt_i="23643" txt_f="23876">The primary cost-effectiveness measures are incremental cost per mm Hg BP reduction from baseline to end of follow-up at 2 years post-randomization and incremental cost per projected CVD disability-adjusted life year (DALY) averted [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="36971" xml_f="36973" txt_i="23876" txt_f="23878">14</offsets></xref><offsets xml_i="36980" xml_f="36982" txt_i="23878" txt_f="23880">, </offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="37015" xml_f="37017" txt_i="23880" txt_f="23882">18</offsets></xref><offsets xml_i="37024" xml_f="37026" txt_i="23882" txt_f="23884">].</offsets></p></sec><sec id="Sec16"><title><offsets xml_i="37059" xml_f="37095" txt_i="23886" txt_f="23922">Secondary cost-effectiveness measure</offsets></title><p><offsets xml_i="37106" xml_f="37218" txt_i="23923" txt_f="24035">The secondary cost-effectiveness measure is incremental cost per QALY gained from baseline to end of follow-up [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="37251" xml_f="37253" txt_i="24035" txt_f="24037">15</offsets></xref><offsets xml_i="37260" xml_f="37261" txt_i="24037" txt_f="24038">–</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="37294" xml_f="37296" txt_i="24038" txt_f="24040">17</offsets></xref><offsets xml_i="37303" xml_f="37305" txt_i="24040" txt_f="24042">].</offsets></p></sec><sec id="Sec17"><title><offsets xml_i="37338" xml_f="37361" txt_i="24044" txt_f="24067">Ancillary study outcome</offsets></title><p><offsets xml_i="37372" xml_f="37533" txt_i="24068" txt_f="24229">The primary outcome for this sub-study is change in 24-h ambulatory mean SBP from baseline to final follow-up. The secondary outcome is 24-h ambulatory mean DBP.</offsets></p><sec id="FPar1"><title><offsets xml_i="37560" xml_f="37576" txt_i="24230" txt_f="24246">Process measures</offsets></title><p><offsets xml_i="37587" xml_f="37794" txt_i="24247" txt_f="24454">Fidelity and quality of implementation will be assessed, and explanations for potential discrepancies in observed and expected outcomes will be sought, which will aid future scale-up. As in the pilot study [</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="37826" xml_f="37827" txt_i="24454" txt_f="24455">5</offsets></xref><offsets xml_i="37834" xml_f="37865" txt_i="24455" txt_f="24486">], these measures will include:</offsets><list list-type="order"><list-item><p><offsets xml_i="37903" xml_f="38013" txt_i="24486" txt_f="24596">Proportion of planned HHE sessions delivered at the household level (HHE session checklist collected from CHW)</offsets></p></list-item><list-item><p><offsets xml_i="38043" xml_f="38194" txt_i="24597" txt_f="24748">Proportion of individuals with hypertension referred by CHW to trained physician (physician referral checklist collected from hypertensive individuals)</offsets></p></list-item><list-item><p><offsets xml_i="38224" xml_f="38374" txt_i="24749" txt_f="24899">Proportion of individuals with hypertension evaluated by trained physician (physician management checklists collected from the district health office)</offsets></p></list-item></list><offsets xml_i="38397" xml_f="38398" txt_i="24900" txt_f="24901">
</offsets></p><p><offsets xml_i="38405" xml_f="38580" txt_i="24902" txt_f="25077">In addition, deviations from the MCI protocol and also participant and health care provider perceptions of the quality and implementation of the intervention will be obtained.</offsets></p></sec></sec></sec><sec id="Sec18"><title><offsets xml_i="38625" xml_f="38645" txt_i="25081" txt_f="25101">Statistical analysis</offsets></title><p><offsets xml_i="38656" xml_f="40664" txt_i="25102" txt_f="27110">All main analyses will be based on the intention-to-treat population so that individuals will be analysed in the arm to which they were randomized, even if they did not adhere to the randomization (e.g. if an individual in the MCI arm did not participate in the MCI intervention). The chief principal investigator (PI) and site PIs will be masked to randomization status of all analytic data. The primary outcome is SBP change from baseline to 2 years. The four 6-monthly changes from baseline measurements (at 6, 12, 18 and 24 months) for all subjects will be modelled simultaneously using a likelihood-based generalized linear mixed model for repeated measures (MMRM) approach. This approach is a subject-level analysis that incorporates a cluster random effect. Although a Gaussian distribution with identity link function is pre-specified for the primary outcome, appropriate distributions within the exponential family and corresponding link functions will be employed in the case of non-normality. An unstructured matrix will be used to model the within-subject variance-covariance structure. If this model fails to converge, other variance-covariance structures will be considered. Primary analyses models will include fixed effects for baseline SBP, country, indicator for distance from clinic (FAR or NEAR), age, gender, intervention arm, visit number and the intervention arm-by-visit number interaction. The primary outcome of interest at 2 years post-randomization will be estimated with corresponding 95% confidence interval using the appropriate contrast at the final visit. Additional analyses will include interactions for country and treatment group to determine whether the effects differ by country. If the interaction effect is found to be clinically meaningful, an MMRM model similar to the primary analysis model will be performed separately for each country. Other analyses (sensitivity, secondary and subgroup analyses) will be explained in a detailed statistical analysis plan paper.</offsets></p></sec><sec id="Sec19"><title><offsets xml_i="40697" xml_f="40708" txt_i="27112" txt_f="27123">Sample size</offsets></title><p><offsets xml_i="40719" xml_f="41387" txt_i="27124" txt_f="27789">The planned sample is 2550 subjects with hypertension, involving 3 strata (countries), with an equal number of clusters per strata (10 clusters per country or 30 clusters total) and similar cluster sizes (85 hypertensive subjects per cluster). Based on findings observed in a previous study in urban Pakistan, and assuming a conservative intraclass correlation coefficient (ICC) of 0.02, 80% follow-up within clusters at 2 years post-randomization (68 hypertensive subjects per cluster) and a two-sided type I error rate of 5%, the trial will provide &gt;99% power for the overall test to detect a difference between arms in SBP reduction as small as 4 (SD 11) mm Hg [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="41419" xml_f="41420" txt_i="27789" txt_f="27790">4</offsets></xref><offsets xml_i="41427" xml_f="41429" txt_i="27790" txt_f="27792">, </offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="41462" xml_f="41464" txt_i="27792" txt_f="27794">14</offsets></xref><offsets xml_i="41471" xml_f="41473" txt_i="27794" txt_f="27796">, </offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="41506" xml_f="41508" txt_i="27796" txt_f="27798">18</offsets></xref><offsets xml_i="41515" xml_f="41627" txt_i="27798" txt_f="27910">]. The study will use 5 mm Hg as the clinically meaningful difference between the two arms for reduction in SBP.</offsets></p><p><offsets xml_i="41634" xml_f="42905" txt_i="27911" txt_f="29179">If heterogeneity in intervention effect across countries is evident (e.g. a reduction in SBP of 3 (SD 11) mm Hg in one country and 9 (SD 16) mm Hg in the other two countries), the trial has 80% power to detect such differences in intervention effects based on the following assumptions: ICC of 0.02 and type I error rate of 1.6% (based on a Bonferroni adjustment), 30 clusters and 85 participants per cluster. In addition to this, the trial has &gt;80% power to detect a difference of 4 mm Hg (SD 11) in SBP reduction between the MCI and usual care arms for each country separately, for an ICC of 0.02, a type I error rate of 5% and 10 clusters of size 85 subjects per country. Furthermore, the high power also ensures that the main effect is adequately powered even after adjusting for dropouts, at both the participant and cluster levels. Therefore, the study is not over-powered for heterogeneity or dropouts (missing data). Power and Sample Size (PASS) software was used for the power calculations. Based on our previous work in urban Pakistan, and expecting a somewhat lower attrition rate in rural areas, the attrition rate is likely to be less than 15% at the end of 2 years in the overall study; therefore, our assumptions about follow-up rates are conservative [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="42937" xml_f="42938" txt_i="29179" txt_f="29180">4</offsets></xref><offsets xml_i="42945" xml_f="42947" txt_i="29180" txt_f="29182">].</offsets></p></sec><sec id="Sec20"><title><offsets xml_i="42980" xml_f="42995" txt_i="29184" txt_f="29199">Data monitoring</offsets></title><p><offsets xml_i="43006" xml_f="43947" txt_i="29200" txt_f="30141">The chief PI (THJ) will be responsible for the overall management of the trial. The day-to-day management at each site will be the responsibility of the site PIs (AN, IJ, AdS). The study management group will comprise the chief PI, statisticians (MG and PA) and validation statistician (ELT), health economists (EAF and MB), qualitative expert (HLQ), site PIs and co-PIs, data managers, project coordinators and research assistants. The Trial Steering Committee (TSC) comprises an independent chair (a senior professor of cardiovascular disease) plus independent experts in statistics, qualitative and mixed-methods research, chronic disease advocacy and health policy and finance. An independent Data Safety and Monitoring Board (DSMB) has been established as per MRC guidelines to review quality and safety issues. The TSC and DSMB operate in line with the MRC terms of reference as amended and agreed on by members at their first meeting.</offsets></p></sec><sec id="Sec21"><title><offsets xml_i="43980" xml_f="44069" txt_i="30143" txt_f="30232">Qualitative study: facilitators and barriers to multicomponent public health intervention</offsets></title><sec id="Sec22"><title><offsets xml_i="44100" xml_f="44120" txt_i="30233" txt_f="30253">Conceptual framework</offsets></title><p><offsets xml_i="44131" xml_f="44410" txt_i="30254" txt_f="30533">The aim of this study is to identify patient and health care provider experience relating to hypertension awareness, treatment and management; this study will be guided by the behaviour change theoretical framework. This framework draws on theories from implementation research [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="44443" xml_f="44445" txt_i="30533" txt_f="30535">19</offsets></xref><offsets xml_i="44452" xml_f="44476" txt_i="30535" txt_f="30559">] and behaviour change [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="44509" xml_f="44511" txt_i="30559" txt_f="30561">20</offsets></xref><offsets xml_i="44518" xml_f="44642" txt_i="30561" txt_f="30685">]. It encapsulates the barriers to hypertension control and makes it possible to explore mediating pathways and moderators [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="44675" xml_f="44677" txt_i="30685" txt_f="30687">21</offsets></xref><offsets xml_i="44684" xml_f="45139" txt_i="30687" txt_f="31142">]. We will explore sub-themes for investigating the implementation of evidence-based practice, organized under three main themes whereby a change in behaviour requires a strong commitment for change (intention barriers), the necessary skills and abilities to perform the behaviour (capability barriers), with no health system constraints, as well as barriers that are external to patients’ or health care providers’ control (health care system barriers) [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="45172" xml_f="45174" txt_i="31142" txt_f="31144">22</offsets></xref><offsets xml_i="45181" xml_f="45183" txt_i="31144" txt_f="31146">].</offsets></p><p><offsets xml_i="45190" xml_f="45847" txt_i="31147" txt_f="31804">The second stage of this study will involve conducting semi-structured interviews with hypertensive individuals, CHWs, health care professionals, providers and policy makers. These interviews will be conducted annually at three time points: prior to the intervention, after 1 year of intervention and after the study completion. The study will adopt a thematic analysis of semi-structured interviews using an adaptation of a behaviour change theoretical framework and a health system’s assessment framework, adopting some techniques of grounded theory such as line-by-line analysis, identifying deviant cases and using the constant comparison method (Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="45881" xml_f="45882" txt_i="31804" txt_f="31805">1</offsets></xref><offsets xml_i="45889" xml_f="45891" txt_i="31805" txt_f="31807">).</offsets><table-wrap id="Tab1"><label><offsets xml_i="45920" xml_f="45927" txt_i="31807" txt_f="31814">Table 1</offsets></label><caption><p><offsets xml_i="45947" xml_f="46002" txt_i="31814" txt_f="31869">Number of participants per country over a 2-year period</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="46068" xml_f="46079" txt_i="31870" txt_f="31881">Time points</offsets><break></break><offsets xml_i="46094" xml_f="46106" txt_i="31881" txt_f="31893">Participants</offsets></th><th><offsets xml_i="46115" xml_f="46136" txt_i="31893" txt_f="31914">Prior to intervention</offsets></th><th><offsets xml_i="46145" xml_f="46177" txt_i="31914" txt_f="31946">After 1 year of the intervention</offsets></th><th><offsets xml_i="46186" xml_f="46219" txt_i="31946" txt_f="31979">After 2 years of the intervention</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="46252" xml_f="46273" txt_i="31979" txt_f="32000">Hypertensive patients</offsets></td><td><offsets xml_i="46282" xml_f="46284" txt_i="32001" txt_f="32003">20</offsets></td><td><offsets xml_i="46293" xml_f="46295" txt_i="32004" txt_f="32006">20</offsets></td><td><offsets xml_i="46304" xml_f="46306" txt_i="32007" txt_f="32009">20</offsets></td></tr><tr><td><offsets xml_i="46324" xml_f="46349" txt_i="32010" txt_f="32035">Health care professionals</offsets></td><td><offsets xml_i="46358" xml_f="46360" txt_i="32036" txt_f="32038">15</offsets></td><td><offsets xml_i="46369" xml_f="46370" txt_i="32039" txt_f="32040">–</offsets></td><td><offsets xml_i="46379" xml_f="46381" txt_i="32041" txt_f="32043">15</offsets></td></tr><tr><td><offsets xml_i="46399" xml_f="46412" txt_i="32044" txt_f="32057">Policy makers</offsets></td><td><offsets xml_i="46421" xml_f="46425" txt_i="32058" txt_f="32062">7–10</offsets></td><td><offsets xml_i="46434" xml_f="46435" txt_i="32063" txt_f="32064">–</offsets></td><td><offsets xml_i="46444" xml_f="46448" txt_i="32065" txt_f="32069">7–10</offsets></td></tr><tr><td><offsets xml_i="46466" xml_f="46471" txt_i="32070" txt_f="32075">Total</offsets></td><td><offsets xml_i="46480" xml_f="46485" txt_i="32076" txt_f="32081">42–45</offsets></td><td><offsets xml_i="46494" xml_f="46496" txt_i="32082" txt_f="32084">20</offsets></td><td><offsets xml_i="46505" xml_f="46510" txt_i="32085" txt_f="32090">42–45</offsets></td></tr></tbody></table></table-wrap><offsets xml_i="46549" xml_f="46550" txt_i="32091" txt_f="32092">
</offsets></p><p><offsets xml_i="46557" xml_f="46937" txt_i="32093" txt_f="32473">The interviews will be audio recorded and translated directly from the respective languages to English on transcripts by an expert bilingual, native speaker. Deductive and inductive data analyses will be used. Relevant quotes representative of the analysis will be incorporated into the publications. Data will be managed and analysed using QSR International’s NVivo 10™ software.</offsets></p></sec></sec><sec id="Sec23"><title><offsets xml_i="46976" xml_f="46995" txt_i="32476" txt_f="32495">Economic evaluation</offsets></title><p><offsets xml_i="47006" xml_f="47789" txt_i="32496" txt_f="33279">Both a budgetary impact analysis and a cost-effectiveness analysis will be performed, the latter using the intention-to-treat principle. The budgetary impact analysis will track the total and per participant costs (including travel time costs monetized at local wage rates) of program delivery using an activity-based costing (ABC) approach. Using this approach, all relevant labor, materials and supplies, contracted services, travel vouchers and opportunity costs required to deliver the interventions will be captured by key activities. This information will not only feed into the cost-effectiveness analysis, but it will also allow policy makers within each country to identify the full and public sector costs of the program, should it be expanded beyond the trial communities.</offsets></p><p><offsets xml_i="47796" xml_f="47902" txt_i="33280" txt_f="33386">The incremental cost-effectiveness evaluation will follow the approach we have employed in prior studies [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="47935" xml_f="47937" txt_i="33386" txt_f="33388">23</offsets></xref><offsets xml_i="47944" xml_f="48533" txt_i="33388" txt_f="33977">] and focus on the additional cost per unit reduction in CVD DALYs relative to standard care. The DALY is a generic measure of the burden of disease that combines healthy life years lost because of premature mortality with those lost due to disability. The metric thus enables assessment of burden of disease and the extent of burden that can be removed due to successful interventions. Using this approach will allow for comparing our results with other programs aimed at improving health outcomes and against common thresholds for cost-effectiveness, such as WHO-CHOICE recommendations [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="48566" xml_f="48568" txt_i="33977" txt_f="33979">24</offsets></xref><offsets xml_i="48575" xml_f="48577" txt_i="33979" txt_f="33981">].</offsets></p><p><offsets xml_i="48584" xml_f="48810" txt_i="33982" txt_f="34208">CVD DALYs averted will be computed using the approach presented in Jafar et al., which assumes a linear relationship between blood pressure and DALYs such that a 1 mm Hg reduction in BP leads to a 2.2% reduction in CVD DALYs [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="48843" xml_f="48845" txt_i="34208" txt_f="34210">14</offsets></xref><offsets xml_i="48852" xml_f="48854" txt_i="34210" txt_f="34212">, </offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="48887" xml_f="48889" txt_i="34212" txt_f="34214">18</offsets></xref><offsets xml_i="48896" xml_f="48898" txt_i="34214" txt_f="34216">].</offsets></p><p><offsets xml_i="48905" xml_f="49134" txt_i="34217" txt_f="34446">In addition, we will quantify incremental costs per QALY gained over the 2-year time period based on the EQ-5D-5L scores. This analysis assumes that there may be benefits to participants irrespective of changes in blood pressure.</offsets></p><p><offsets xml_i="49141" xml_f="49670" txt_i="34447" txt_f="34976">All analyses will be conducted from a societal perspective (including payer and participant costs and benefits) and separately from a third party payer’s perspective, as results from the latter may be most relevant to potential government payers. Results will be estimated for the three countries together for wider generalizability to South Asia and other low and/or middle income countries (LMICs), and for each country separately for local applicability, and will be compared to established benchmarks for cost-effectiveness [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="49703" xml_f="49705" txt_i="34976" txt_f="34978">25</offsets></xref><offsets xml_i="49712" xml_f="49727" txt_i="34978" txt_f="34993">]. One-way and </offsets><italic><offsets xml_i="49735" xml_f="49736" txt_i="34993" txt_f="34994">n</offsets></italic><offsets xml_i="49745" xml_f="50121" txt_i="34994" txt_f="35370">-way sensitivity analyses and cost-effectiveness acceptability curves that graphically present the probability that the MCI is cost-effective for a range of willingness-to-pay metrics that a decision maker may consider will also be presented. Based on the results, we will discuss the extent to which the MCI is likely to be cost-effective in rural communities in other LMICs.</offsets></p></sec></sec><sec id="Sec24"><title><offsets xml_i="50160" xml_f="50170" txt_i="35373" txt_f="35383">Discussion</offsets></title><p><offsets xml_i="50181" xml_f="50347" txt_i="35384" txt_f="35550">High BP is the leading attributable risk factor for disability and mortality from CVD globally, and it accounts for a third of age-standardized deaths in South Asia [</offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="50380" xml_f="50382" txt_i="35550" txt_f="35552">26</offsets></xref><offsets xml_i="50389" xml_f="50599" txt_i="35552" txt_f="35762">]. The early age of onset of CVD in South Asians worsens the consequences through a reduction in productive life years. About one in four adults suffers from hypertension in Bangladesh, Pakistan and Sri Lanka [</offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="50632" xml_f="50634" txt_i="35762" txt_f="35764">27</offsets></xref><offsets xml_i="50641" xml_f="50642" txt_i="35764" txt_f="35765">–</offsets><xref ref-type="bibr" rid="CR29"><offsets xml_i="50675" xml_f="50677" txt_i="35765" txt_f="35767">29</offsets></xref><offsets xml_i="50684" xml_f="50853" txt_i="35767" txt_f="35936">]. Evidence on effective health systems strategies to manage hypertension is limited, especially in rural South Asia where case fatality rates from CVD are even higher [</offsets><xref ref-type="bibr" rid="CR30"><offsets xml_i="50886" xml_f="50888" txt_i="35936" txt_f="35938">30</offsets></xref><offsets xml_i="50895" xml_f="50897" txt_i="35938" txt_f="35940">].</offsets></p><p><offsets xml_i="50904" xml_f="51593" txt_i="35941" txt_f="36630">In the COBRA-BPS study, we will evaluate the effectiveness and cost-effectiveness of a comprehensive ‘multicomponent intervention (MCI)’ for effective delivery of hypertension care using the rural predominantly public primary care infrastructure. The MCI approach has been modified from a two-component strategy of HHE and training of GPs, previously shown to be successful in an urban private practice setting, into a five-component MCI with the additional components essential for monitoring of individuals with poorly controlled hypertension and sustainable care delivery via subsidies for travel to clinic and antihypertensive medications through the public health care infrastructure.</offsets></p><p><offsets xml_i="51600" xml_f="52345" txt_i="36631" txt_f="37376">The MCI is also expected to strengthen the capacity of the health system by establishing a team-based approach and referral links with documentation of standardized care to enhance hypertension management. The trial uses hypertension as an entry point into developing rural NCD health services, and the HHE component of our intervention is the first-line approach for management of diabetes and other common NCDs. The use of statins among individuals at high risk for CVD follows an up-to-date comprehensive CVD risk reduction strategy. Models of coordinated care are recommended by the World Health Organization (WHO) for communicable disease programs, such as directly observed treatment (DOT) for tuberculosis, HIV and management of malaria [</offsets><xref ref-type="bibr" rid="CR31"><offsets xml_i="52378" xml_f="52380" txt_i="37376" txt_f="37378">31</offsets></xref><offsets xml_i="52387" xml_f="53026" txt_i="37378" txt_f="38017">]. Our trial will provide direct evidence of the value of using comparable models and platforms for NCD management. Furthermore, the training components in the intervention leverage the existing infrastructure and will create economies of scale during roll out at national and regional levels if the trial is successful. NCDs have recently been featured on the national health policy agenda in Bangladesh, Pakistan and Sri Lanka. Contrasting the experiences from these three countries should provide valuable lessons to implement an action plan and also validate the usefulness of our approach for other countries in the region and beyond.</offsets></p></sec><sec id="Sec25"><title><offsets xml_i="53059" xml_f="53071" txt_i="38019" txt_f="38031">Trial status</offsets></title><p><offsets xml_i="53082" xml_f="53224" txt_i="38032" txt_f="38174">Participants are currently being recruited. The first patient was enrolled in April 2016. The study SPIRIT timeline details are shown in Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="53256" xml_f="53257" txt_i="38174" txt_f="38175">1</offsets></xref><offsets xml_i="53264" xml_f="53265" txt_i="38175" txt_f="38176">.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="53321" xml_f="53337" txt_i="38178" txt_f="38194">Additional files</offsets></title><sec id="Sec26"><p><offsets xml_i="53364" xml_f="53365" txt_i="38195" txt_f="38196">
</offsets><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13063_2017_2018_MOESM1_ESM.pdf"><label><offsets xml_i="53485" xml_f="53503" txt_i="38196" txt_f="38214">Additional file 1:</offsets></label><caption><p><offsets xml_i="53523" xml_f="53553" txt_i="38214" txt_f="38244">SPIRIT checklist. (PDF 136 kb)</offsets></p></caption></media></supplementary-material><offsets xml_i="53600" xml_f="53601" txt_i="38245" txt_f="38246">
</offsets><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13063_2017_2018_MOESM2_ESM.pdf"><label><offsets xml_i="53721" xml_f="53739" txt_i="38246" txt_f="38264">Additional file 2:</offsets></label><caption><p><offsets xml_i="53759" xml_f="53805" txt_i="38264" txt_f="38310">Summary of intervention trainings. (PDF 13 kb)</offsets></p></caption></media></supplementary-material><offsets xml_i="53852" xml_f="53853" txt_i="38311" txt_f="38312">
</offsets><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="13063_2017_2018_MOESM3_ESM.pdf"><label><offsets xml_i="53973" xml_f="53991" txt_i="38312" txt_f="38330">Additional file 3:</offsets></label><caption><p><offsets xml_i="54011" xml_f="54038" txt_i="38330" txt_f="38357">CHW checklist. (PDF 175 kb)</offsets></p></caption></media></supplementary-material><offsets xml_i="54085" xml_f="54086" txt_i="38358" txt_f="38359">
</offsets><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="13063_2017_2018_MOESM4_ESM.pdf"><label><offsets xml_i="54206" xml_f="54224" txt_i="38359" txt_f="38377">Additional file 4:</offsets></label><caption><p><offsets xml_i="54244" xml_f="54281" txt_i="38377" txt_f="38414">GP management checklist. (PDF 145 kb)</offsets></p></caption></media></supplementary-material><offsets xml_i="54328" xml_f="54329" txt_i="38415" txt_f="38416">
</offsets><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="13063_2017_2018_MOESM5_ESM.pdf"><label><offsets xml_i="54449" xml_f="54467" txt_i="38416" txt_f="38434">Additional file 5:</offsets></label><caption><p><offsets xml_i="54487" xml_f="54522" txt_i="38434" txt_f="38469">GP referral checklist. (PDF 127 kb)</offsets></p></caption></media></supplementary-material><offsets xml_i="54569" xml_f="54570" txt_i="38470" txt_f="38471">
</offsets><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="13063_2017_2018_MOESM6_ESM.pdf"><label><offsets xml_i="54690" xml_f="54708" txt_i="38471" txt_f="38489">Additional file 6:</offsets></label><caption><p><offsets xml_i="54728" xml_f="54789" txt_i="38489" txt_f="38550">Antihypertensive Medication Treatment Algorithm. (PDF 651 kb)</offsets></p></caption></media></supplementary-material><offsets xml_i="54836" xml_f="54837" txt_i="38551" txt_f="38552">
</offsets></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BPS</term><def><p>Bangladesh, Pakistan, Sri Lanka</p></def></def-item><def-item><term>CHW</term><def><p>Community health worker</p></def></def-item><def-item><term>COBRA</term><def><p>Control of Blood Pressure and Risk Attenuation</p></def></def-item><def-item><term>CVD</term><def><p>Cardiovascular disease</p></def></def-item><def-item><term>GP</term><def><p>General practitioner</p></def></def-item><def-item><term>HHE</term><def><p>Home health education</p></def></def-item><def-item><term>MCI</term><def><p>Multicomponent intervention</p></def></def-item><def-item><term>SPIRIT</term><def><p>Standard Protocol Items: Recommendations for Interventional Trials</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13063-017-2018-0) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to acknowledge the members of the Trial Steering Committee and Data Safety and Monitoring Board.</p><p>
<italic>Trial Steering Committee members:</italic> Prof Joep Perk (chair), Senior Professor</p><p>Linnaeus University, Sweden; Dr Richard Smith, Prof Anne Mills, Dr Elizabeth Allen,London School of Hygiene and Tropical Medicine, United Kingdom;, Dr Kate Hunt, University of Glasgow, UK</p><p>
<italic>Data Safety and Monitoring Board:</italic> Prof Andrew Farmer (chair), Professor of General Practice University of Oxford, United Kingdom; Dr Bruce Neal, University of Sydney, Australia; Prof Doris Young, University of Melbourne, Australia; Dr Say Beng Tan, Duke-NUS Medical School, Singapore <italic>The International Advisory Board</italic> will be chaired by Dr Sania Nishtar, President Heartfile (non-government organization), Pakistan.</p><sec id="FPar2"><title>Funding</title><p>The study is supported by a research award: Grant Ref No: MR/N006178/1 from the MRC/DFId/Wellcome Trust, UK. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec id="FPar4"><title>Authors’ contributions</title><p>THJ conceived the design of the trial, drafted the protocol and assembled the site teams and project management teams. AN, IJ and AdS with co-site PIs (JC, AH, AK) contributed to modifications and adaptions in the protocol as per local health systems in each country; MG and PA led the analytic plan, ELT also contributed to the analytic plan, EAF led the cost-effectiveness plan, MB contributed to the CEA plan and HLQ led the qualitative interviews planning. THJ assembled the TSC and DSMB with SE. THJ approved all components of the study and is the guarantor. All authors read and approved the final manuscript.</p></sec><sec id="FPar5"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar7"><title>Ethics approval and consent to participate</title><p>Ethical approval has been obtained from the Ethics Review Committee at the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore (NUS reference code: B-15-253), the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) in Dhaka, Bangladesh (ERC NO: PR-15104), the Aga Khan University (AKU) in Karachi, Pakistan (ERC Ref. No: 3833-CHS-ERC-15), the University of Kelaniya (UKe) in Colombo, Sri Lanka (ERC Ref. No: P/179/11/2015) and the London School of Hygiene and Tropical Medicine (LSHTM) in the UK (LSHTM Ethics Ref: 10361).</p></sec><sec id="FPar8"><title>Informed consent</title><p>Written informed consent will be obtained prior to participant involvement in the study from: (1) hypertensive individuals in the pre- and post-intervention study, (2) stakeholders and 3) individuals who participate in interview sessions to investigate stakeholder experiences and attitudes towards the study intervention. The consent form is held by institutions (ICCDR, B, AKU and Uke) and is available for review by the Chief Investigator (THJ).</p></sec><sec id="FPar9"><title>Dissemination plan</title><p>
<italic>National Advisory Group:</italic> Each site is supported by the relevant provincial and national health officials, and members of professional organizations (cardiac and hypertension societies) and key stakeholders will serve on a ‘national advisory group’. This group has already been sensitized to the MCI strategies and their feedback incorporated into the trial. Regular meetings and dissemination of results are likely to enhance the scale-up of the trial.</p><p>
<italic>International Advisory Board:</italic> This board will include senior government representatives from WHO and Bangladesh, Pakistan and Sri Lanka, key health policy advocates and academic leadership.</p></sec><sec id="FPar10"><title>Trial governance and management</title><p>The trial is conducted per UK-MRC GCP framework with an independent Trial Steering Committee and Data Safety and Monitoring Board.</p></sec><sec id="FPar11"><title>Publisher’s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>AD</given-names></name><name><surname>Mathers</surname><given-names>CD</given-names></name><name><surname>Ezzati</surname><given-names>M</given-names></name><name><surname>Jamison</surname><given-names>DT</given-names></name><name><surname>Murray</surname><given-names>CJ</given-names></name></person-group><article-title>Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data</article-title><source>Lancet</source><year>2006</year><volume>367</volume><fpage>1747</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)68770-9</pub-id><pub-id pub-id-type="pmid">16731270</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Foreman</surname><given-names>K</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Aboyans</surname><given-names>V</given-names></name><name><surname>Abraham</surname><given-names>J</given-names></name><name><surname>Adair</surname><given-names>T</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Ahn</surname><given-names>SY</given-names></name><etal></etal></person-group><article-title>Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>2095</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61728-0</pub-id><pub-id pub-id-type="pmid">23245604</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forouzanfar</surname><given-names>MH</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Roth</surname><given-names>GA</given-names></name><name><surname>Ng</surname><given-names>M</given-names></name><name><surname>Biryukov</surname><given-names>S</given-names></name><name><surname>Marczak</surname><given-names>L</given-names></name><name><surname>Alexander</surname><given-names>L</given-names></name><name><surname>Estep</surname><given-names>K</given-names></name><name><surname>Abate</surname><given-names>KH</given-names></name><name><surname>Akinyemiju</surname><given-names>TF</given-names></name></person-group><article-title>Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015</article-title><source>JAMA</source><year>2017</year><volume>317</volume><fpage>165</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.19043</pub-id><pub-id pub-id-type="pmid">28097354</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafar</surname><given-names>TH</given-names></name><name><surname>Hatcher</surname><given-names>J</given-names></name><name><surname>Poulter</surname><given-names>N</given-names></name><name><surname>Islam</surname><given-names>M</given-names></name><name><surname>Hashmi</surname><given-names>S</given-names></name><name><surname>Qadri</surname><given-names>Z</given-names></name><name><surname>Bux</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Jafary</surname><given-names>FH</given-names></name><name><surname>Hameed</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Community-based interventions to promote blood pressure control in a developing country: a cluster randomized trial</article-title><source>Ann Intern Med</source><year>2009</year><volume>151</volume><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-151-9-200911030-00004</pub-id><pub-id pub-id-type="pmid">19884620</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafar</surname><given-names>TH</given-names></name><name><surname>de Silva</surname><given-names>A</given-names></name><name><surname>Naheed</surname><given-names>A</given-names></name><name><surname>Jehan</surname><given-names>I</given-names></name><name><surname>Liang</surname><given-names>F</given-names></name><name><surname>Assam</surname><given-names>PN</given-names></name><name><surname>Legido-Quigley</surname><given-names>H</given-names></name><name><surname>Finkelstein</surname><given-names>EA</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name><name><surname>Wickremasinghe</surname><given-names>R</given-names></name></person-group><article-title>Control of blood pressure and risk attenuation: a public health intervention in rural Bangladesh, Pakistan, and Sri Lanka: feasibility trial results</article-title><source>J Hypertens</source><year>2016</year><volume>34</volume><fpage>1872</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000001014</pub-id><pub-id pub-id-type="pmid">27488552</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGorrian</surname><given-names>C</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Islam</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>H</given-names></name><name><surname>Rangarajan</surname><given-names>S</given-names></name><name><surname>Avezum</surname><given-names>A</given-names></name><name><surname>Prabhakaran</surname><given-names>D</given-names></name><name><surname>Almahmeed</surname><given-names>W</given-names></name><name><surname>Rumboldt</surname><given-names>Z</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>581</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehq448</pub-id><pub-id pub-id-type="pmid">21177699</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. 2016. <ext-link ext-link-type="uri" xlink:href="http://guidance.nice.org.uk/CG127/QuickRefGuide/pdf/English">http://guidance.nice.org.uk/CG127/QuickRefGuide/pdf/English</ext-link>. Accessed 12 Feb 2017.</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>A</given-names></name><name><surname>Steel</surname><given-names>S</given-names></name><name><surname>Freeman</surname><given-names>P</given-names></name><name><surname>de Greeff</surname><given-names>A</given-names></name><name><surname>Shennan</surname><given-names>A</given-names></name></person-group><article-title>Validation of the Omron M7 (HEM-780-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol</article-title><source>Blood Press Monit</source><year>2008</year><volume>13</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1097/MBP.0b013e3282cb57b6</pub-id><pub-id pub-id-type="pmid">18199924</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijewardene</surname><given-names>K</given-names></name><name><surname>Mohideen</surname><given-names>M</given-names></name><name><surname>Mendis</surname><given-names>S</given-names></name><name><surname>Fernando</surname><given-names>D</given-names></name><name><surname>Kulathilaka</surname><given-names>T</given-names></name><name><surname>Weerasekara</surname><given-names>D</given-names></name></person-group><article-title>Prevalence of hypertension, diabetes and obesity: baseline findings of a population based survey in four provinces in Sri Lanka</article-title><source>Ceylon Med J</source><year>2005</year><volume>50</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">16114771</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafar</surname><given-names>TH</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Jafary</surname><given-names>FH</given-names></name><name><surname>White</surname><given-names>F</given-names></name><name><surname>Gul</surname><given-names>A</given-names></name><name><surname>Rahbar</surname><given-names>MH</given-names></name><name><surname>Khan</surname><given-names>AQ</given-names></name><name><surname>Hattersley</surname><given-names>A</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Chaturvedi</surname><given-names>N</given-names></name></person-group><article-title>Ethnic subgroup differences in hypertension in Pakistan</article-title><source>J Hypertens</source><year>2003</year><volume>21</volume><fpage>905</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1097/00004872-200305000-00014</pub-id><pub-id pub-id-type="pmid">12714864</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GK</given-names></name><name><surname>Wang</surname><given-names>HH</given-names></name><name><surname>Liu</surname><given-names>KQ</given-names></name><name><surname>Cheung</surname><given-names>Y</given-names></name><name><surname>Morisky</surname><given-names>DE</given-names></name><name><surname>Wong</surname><given-names>MC</given-names></name></person-group><article-title>Determinants of medication adherence to antihypertensive medications among a Chinese population using Morisky Medication Adherence Scale</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e62775</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0062775</pub-id><pub-id pub-id-type="pmid">23638143</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mente</surname><given-names>A</given-names></name><name><surname>O’Donnell</surname><given-names>MJ</given-names></name><name><surname>Rangarajan</surname><given-names>S</given-names></name><name><surname>McQueen</surname><given-names>MJ</given-names></name><name><surname>Poirier</surname><given-names>P</given-names></name><name><surname>Wielgosz</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Di</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Association of urinary sodium and potassium excretion with blood pressure</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>601</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1311989</pub-id><pub-id pub-id-type="pmid">25119606</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calder</surname><given-names>J</given-names></name><name><surname>Schachter</surname><given-names>M</given-names></name><name><surname>Sever</surname><given-names>P</given-names></name></person-group><article-title>Ion channel involvement in the acute vascular effects of thiazide diuretics and related compounds</article-title><source>J Pharmacol Exp Ther</source><year>1993</year><volume>265</volume><fpage>1175</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">7685385</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafar</surname><given-names>T</given-names></name><name><surname>Islam</surname><given-names>M</given-names></name><name><surname>Bux</surname><given-names>R</given-names></name><name><surname>Poulter</surname><given-names>N</given-names></name><name><surname>Hatcher</surname><given-names>J</given-names></name><name><surname>Chaturvedi</surname><given-names>N</given-names></name></person-group><article-title>Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial</article-title><source>Circulation</source><year>2011</year><volume>124</volume><fpage>1615</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.039990</pub-id><pub-id pub-id-type="pmid">21931077</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Dwyer-Lindgren</surname><given-names>L</given-names></name><name><surname>Lofgren</surname><given-names>KT</given-names></name><name><surname>Rajaratnam</surname><given-names>JK</given-names></name><name><surname>Marcus</surname><given-names>JR</given-names></name><name><surname>Levin-Rector</surname><given-names>A</given-names></name><name><surname>Levitz</surname><given-names>CE</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name><name><surname>Murray</surname><given-names>CJ</given-names></name></person-group><article-title>Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>2071</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61719-X</pub-id><pub-id pub-id-type="pmid">23245603</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Yu</surname><given-names>XQ</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>MH</given-names></name><name><surname>Li</surname><given-names>ZG</given-names></name><name><surname>Zhang</surname><given-names>NZ</given-names></name><name><surname>Shao</surname><given-names>SJ</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable chronic obstructive pulmonary disease: a randomized, double-blind, double-dummy, active-controlled, 4-center study</article-title><source>J Ethnopharmacol</source><year>2012</year><volume>141</volume><fpage>584</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.08.060</pub-id><pub-id pub-id-type="pmid">21911051</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Flaxman</surname><given-names>AD</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Michaud</surname><given-names>C</given-names></name><name><surname>Ezzati</surname><given-names>M</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Salomon</surname><given-names>JA</given-names></name><name><surname>Abdalla</surname><given-names>S</given-names></name><name><surname>Aboyans</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>2163</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61729-2</pub-id><pub-id pub-id-type="pmid">23245607</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakicic</surname><given-names>JM</given-names></name><name><surname>Tate</surname><given-names>DF</given-names></name><name><surname>Lang</surname><given-names>W</given-names></name><name><surname>Davis</surname><given-names>KK</given-names></name><name><surname>Polzien</surname><given-names>K</given-names></name><name><surname>Rickman</surname><given-names>AD</given-names></name><name><surname>Erickson</surname><given-names>K</given-names></name><name><surname>Neiberg</surname><given-names>RH</given-names></name><name><surname>Finkelstein</surname><given-names>EA</given-names></name></person-group><article-title>Effect of a stepped-care intervention approach on weight loss in adults: a randomized clinical trial</article-title><source>JAMA</source><year>2012</year><volume>307</volume><fpage>2617</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.6866</pub-id><pub-id pub-id-type="pmid">22735431</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michie</surname><given-names>S</given-names></name><name><surname>Johnston</surname><given-names>M</given-names></name><name><surname>Abraham</surname><given-names>C</given-names></name><name><surname>Lawton</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>A</given-names></name><name><surname>Psychological</surname><given-names>TG</given-names></name></person-group><article-title>Making psychological theory useful for implementing evidence based practice: a consensus approach</article-title><source>Qual Saf Health Care</source><year>2005</year><volume>14</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1136/qshc.2004.011155</pub-id><pub-id pub-id-type="pmid">15692000</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishbein</surname><given-names>M</given-names></name></person-group><article-title>The role of theory in HIV prevention</article-title><source>AIDS Care</source><year>2000</year><volume>12</volume><fpage>273</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1080/09540120050042918</pub-id><pub-id pub-id-type="pmid">10928203</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Walker</surname><given-names>AE</given-names></name><name><surname>Grimshaw</surname><given-names>JM</given-names></name></person-group><article-title>A systematic review of the use of theory in the design of guideline dissemination and implementation strategies and interpretation of the results of rigorous evaluations</article-title><source>Implement Sci</source><year>2010</year><volume>5</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1748-5908-5-14</pub-id><pub-id pub-id-type="pmid">20047652</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>The world health report 2000: health systems: improving performance</source><year>2000</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faqah</surname><given-names>A</given-names></name><name><surname>Jafar</surname><given-names>TH</given-names></name></person-group><article-title>Control of blood pressure in chronic kidney disease: how low to go?</article-title><source>Nephron Clin Pract</source><year>2011</year><volume>119</volume><fpage>c324</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1159/000331066</pub-id><pub-id pub-id-type="pmid">22135791</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). 2017. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/choice/costs/CER_levels/en/">http://www.who.int/choice/costs/CER_levels/en/</ext-link>. Accessed 17 May 2017.</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Baltussen RMPM, Adam T, Tan-Torres Edejer T, Hutubessy RCW, Acharya A, Evans DB, Murray CJL. Making Choices in Health: WHO Guide to Cost Effectiveness Analysis. Geneva:World Health Organization; 2003.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>SS</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Flaxman</surname><given-names>AD</given-names></name><name><surname>Danaei</surname><given-names>G</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Adair-Rohani</surname><given-names>H</given-names></name><name><surname>Amann</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>HR</given-names></name><name><surname>Andrews</surname><given-names>KG</given-names></name><name><surname>Aryee</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>2224</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61766-8</pub-id><pub-id pub-id-type="pmid">23245609</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafar</surname><given-names>TH</given-names></name><name><surname>Jessani</surname><given-names>S</given-names></name><name><surname>Jafary</surname><given-names>FH</given-names></name><name><surname>Ishaq</surname><given-names>M</given-names></name><name><surname>Orakzai</surname><given-names>R</given-names></name><name><surname>Orakzai</surname><given-names>S</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Chaturvedi</surname><given-names>N</given-names></name></person-group><article-title>General practitioners’ approach to hypertension in urban Pakistan: disturbing trends in practice</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>1278</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000157698.78949.D7</pub-id><pub-id pub-id-type="pmid">15769769</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>AK</given-names></name><name><surname>Majumder</surname><given-names>AA</given-names></name></person-group><article-title>Hypertension in Bangladesh: a review</article-title><source>Indian Heart J</source><year>2012</year><volume>64</volume><fpage>319</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/S0019-4832(12)60096-0</pub-id><pub-id pub-id-type="pmid">22664819</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katulanda</surname><given-names>P</given-names></name><name><surname>Ranasinghe</surname><given-names>P</given-names></name><name><surname>Jayawardena</surname><given-names>R</given-names></name><name><surname>Constantine</surname><given-names>GR</given-names></name><name><surname>Rezvi Sheriff</surname><given-names>MH</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name></person-group><article-title>The prevalence, predictors and associations of hypertension in Sri Lanka: a cross-sectional population based national survey</article-title><source>Clin Exp Hypertens</source><year>2014</year><volume>36</volume><fpage>484</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.3109/10641963.2013.863321</pub-id><pub-id pub-id-type="pmid">24433043</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Rangarajan</surname><given-names>S</given-names></name><name><surname>Teo</surname><given-names>K</given-names></name><name><surname>Islam</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Bo</surname><given-names>J</given-names></name><name><surname>Lou</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Cardiovascular risk and events in 17 low-, middle-, and high-income countries</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>818</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1311890</pub-id><pub-id pub-id-type="pmid">25162888</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conseil</surname><given-names>A</given-names></name><name><surname>Mounier-Jack</surname><given-names>S</given-names></name><name><surname>Coker</surname><given-names>R</given-names></name></person-group><article-title>Integration of health systems and priority health interventions: a case study of the integration of HIV and TB control programmes into the general health system in Vietnam</article-title><source>Health Policy Plan</source><year>2010</year><volume>25</volume><issue>Suppl 1</issue><fpage>i32</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/heapol/czq055</pub-id><pub-id pub-id-type="pmid">20966106</pub-id></element-citation></ref></ref-list></back></article>